News & Updates

A simple urine test looking at genetic mutations in DNA predicts urothelial cancer – the most common type of bladder cancer – 12 years before patients develop symptoms in a recent study.

The addition of pembrolizumab to standard chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, regardless of whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease, according to the NRG-GY018 trial presented at the SGO 2023.

A linear pharmacokinetics characterizes tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 human monoclonal antibody of the immunoglobulin G2 κ isotype, in patients with advanced solid tumours, reveals a study.

Undergoing supracervical hysterectomy during colorectal resection seems to reduce the duration of the procedure, the need for blood transfusion, as well as the length of hospital stay, according to a study presented at the 2023 SGO Annual Meeting on Women’s Cancer.

Patients with brain metastasis from gynaecologic cancers often present with an advanced stage disease and have had at least one prior recurrence, according to a study. In addition, the presence of an extracranial disease is common at the time of brain metastasis diagnosis.

Adding dostarlimab, an immune checkpoint inhibitor, to standard-of-care chemotherapy significantly improves progression-free survival (PFS) in patients with primary advanced or recurrent endometrial cancer, including those with dMMR-MSI-H* disease, according to the first interim analysis of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial presented at SGO 2023.

Maximal endoscopic ablation prior to treatment with reverse thermal polymer gel of mitomycin C (UGN-101) treatment appears to lead to fewer patients with upper tract urothelial carcinoma at first endoscopy and fewer adverse events (AEs) when compared with primary chemoablative therapy, suggests a recent study.